Telemedicine After the Pandemic: What Actually Stuck in India

The 2021 forecasts were confident: telemedicine would become the default first touchpoint for Indian healthcare, in-person visits would become the exception for routine care, and rural India would leapfrog straight to video consults. Four years on, the picture that actually stuck is narrower and more interesting than either the boosters or the skeptics predicted.

What stuck

• •Follow-up consultations for chronic conditions, diabetes, hypertension, thyroid management, where a video or even audio call to adjust a prescription doesn't require a physical exam
• •Second opinions from specialists in metro hospitals, sought by patients in smaller towns who would otherwise have travelled 3-6 hours
• •Prescription renewals and lab report reviews, which now account for a large share of teleconsult volume at most listed hospital chains

What didn't

First-time consultations for anything beyond the mildest complaints never really moved online. Patients, and doctors, still want a physical exam for a new complaint, and diagnostic dependency rules out a huge share of first visits from ever being tele-only. Rural adoption also plateaued well below projections: connectivity is only part of the story, the bigger barrier is trust in a doctor the patient has never met in person, and a preference for a known local practitioner even for a shorter, worse consultation.

The number that matters

Teleconsult volume across major Indian digital health platforms settled at roughly 4x pre-pandemic levels by 2023 and has been flat since, not the 15-20x some 2021 projections assumed. That flatness is itself the signal: this isn't a market still in early adoption, it's a market that has found its actual ceiling for the current generation of tools.

The businesses that misread this, building for a future where teleconsultation displaces in-person primary care, are now sitting on underused capacity. The ones that read it correctly built teleconsultation as a companion channel to physical care, specifically for follow-up and chronic management, and that's the segment still growing at a healthy clip: 20-25% year on year, off a now-realistic base.